1044 (1044) Fair Value & Analysis

Consumer Defensive · Market cap HK$25.0B

1 1044 1044 · HK

PriceHK$21.74

Fair ValueHK$53.40

Upside+145.6%

Quality60/100

Evidence: High Range HK$40.05 – HK$66.75

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Share price −10.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$20.30 – HK$28.62 · fair‑value band HK$40.05 – HK$66.75 · the HK$21.74 price screens below the HK$53.40 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1044 (1044) currently trades at HK$21.74, while our model-based Fair Value estimate is HK$53.40 — implying the stock looks roughly 145.6% undervalued today. We read business quality at 60/100 (solid quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1044 generated revenue of HK$23.1B at a net margin of 11.0%. Revenue grew 3.9% year over year. It earns a return on equity of 11.8%. Net debt stands at HK$145M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$23.1B

Revenue growth (YoY) +3.9%

Net margin 11.0%

Return on equity 11.8%

Free cash flow HK$2.2B FY2025

P/E ratio 8.5

More key figures

Operating margin 10.5%

EPS (TTM) HK$1.21

Dividend yield 6.4%

EPS growth (YoY) +30.8%

Net debt HK$145M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1044 reported revenue of HK$23.1B in FY2025 versus HK$20.8B in FY2021, a compound +2.6%/yr. Reported net income was HK$2.5B in FY2025, compounding −6.2%/yr from FY2021.

Revenue +2.6%/yr

FY21 HK$20.8B

FY22 HK$22.6B

FY23 HK$23.8B

FY24 HK$22.7B

FY25 HK$23.1B

Net income −6.2%/yr

FY21 HK$3.3B

FY22 HK$1.9B

FY23 HK$2.8B

FY24 HK$2.3B

FY25 HK$2.5B

Is 1044 fairly valued? → Check now

Similar stocks

6 more Household & Personal Products stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
PG PG	2,590 MXN	108.66 MXN	-96%
The Procter & Gamble Company PGCO34	R$54.71	R$7.69	-86%
L'Oréal S.A LRLCF	$445.77	$275.67	-38%
Unilever PLC UNLYF	$59.34	$46.11	-22%
Colgate-Palmolive Company CPA	€77.60	€36.69	-53%
Hindustan Unilever Limited HINDUNILVR	₹2,170	₹807.38	-63%

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1044 (1044) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$53.40 versus a price of HK$21.74 — about +146% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1044?

Our model-based fair value for 1044 is HK$53.40 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$21.74.

What is the quality score of 1044?

1044 has a Quality Score of 60/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1044 (1044)?

1044 reported trailing-twelve-month revenue of about HK$23.1B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1044?

The net profit margin of 1044 is about 11.0%, meaning it keeps roughly 11.0% of revenue as net income. Based on the latest reported figures.

Does 1044 pay a dividend?

1044 currently shows a dividend yield of about 6.36% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.